2,822
Views
3
CrossRef citations to date
0
Altmetric
Research Paper

Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population

ORCID Icon, , , , ORCID Icon, , , & ORCID Icon show all
Pages 1404-1412 | Received 20 Sep 2019, Accepted 17 Nov 2019, Published online: 20 Dec 2019

References

  • Martin T, Parker SE, Hedstrom R, Le T, Hoffman SL, Norman J, Hobart P, Lew D. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther. 1999;10:759–68. doi:10.1089/10430349950018517.
  • Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995;772:30–39. doi:10.1111/nyas.1995.772.issue-1.
  • Morrow MP, Kraynyak KA, Sylvester AJ, Shen X, Amante D, Sakata L, Parker L, Yan J, Boyer J, Roh C, et al. Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100. Mol Ther Oncolytics. 2016;3:16025. doi:10.1038/mto.2016.25.
  • Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998;16:867–70. doi:10.1038/nbt0998-867.
  • Gehl J, Mir LM. Determination of optimal parameters for in vivo gene transfer by electroporation, using a rapid in vivo test for cell permeabilization. Biochem Biophys Res Commun. 1999;261:377–80. doi:10.1006/bbrc.1999.1014.
  • Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi:10.1002/(ISSN)1097-0258.
  • Santesso N, Mustafa RA, Wiercioch W, Kehar R, Gandhi S, Chen Y, Cheung A, Hopkins J, Khatib R, Ma B, et al. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2016;132:266–71. doi:10.1016/j.ijgo.2015.07.026.
  • Kyrgiou M, Athanasiou A, Paraskevaidi M, Mitra A, Kalliala I,Martin-Hirsch P, Arbyn M, Bennett P, Paraskevaidis E. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633.
  • Xi LF, Kiviat NB, Wheeler CM, Kreimer A, Ho J, Koutsky LA. Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants. J Infect Dis. 2007;195:1340–44. doi:10.1086/522476.
  • Nobbenhuis MA, Meijer CJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Risse EK, Verheijen RHM, Helmerhorst TJM. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer. 2001;84:796–801. doi:10.1054/bjoc.2000.1689.
  • Committee Opinion No.675. Management of vulvar intraepithelial Neoplasia. Obstet Gynecol. 2016;128:e178–82. doi:10.1097/AOG.0000000000001713.
  • Frega A, Sopracordevole F, Scirpa P, Biamonti A, Lorenzon L, Scarani S, De Sanctis L, Pacchiarotti A, Moscarini M, French D, et al. The re-infection rate of high-risk HPV and the recurrence rate of vulvar intraepithelial neoplasia (VIN) usual type after surgical treatment. Med Sci Monit. 2011;17:Cr532–5. doi:10.12659/MSM.881941.
  • Long KC, Menon R, Bastawrous A, Billingham R. Screening, surveillance, and treatment of anal intraepithelial Neoplasia. Clin Colon Rectal Surg. 2016;29:57–64. doi:10.1055/s-00000049.
  • Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, Fredua B, Stokley S. National, Regional, State, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2017. Mmwr-morbid Mortal W. 2018;67:909–17. doi:10.15585/mmwr.mm6733a1.
  • Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Fredua B, Singleton JA, Stokley S, et al. National, Regional, State, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2018. Mmwr-morbid Mortal W. 2019;68:718–23. doi:10.15585/mmwr.mm6833a2.
  • Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136:189–97. doi:10.1016/j.ygyno.2014.11.076.
  • Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078–88. doi:10.1016/S0140-6736(15)00239-1.